Mechanisms of Local Immunoresistance in Glioma

被引:58
作者
Albesiano, Emilia [2 ]
Han, James E. [1 ]
Lim, Michael [1 ]
机构
[1] Johns Hopkins Univ, Sch Med, Dept Neurosurg, Baltimore, MD 21231 USA
[2] Johns Hopkins Univ, Sch Med, Dept Oncol, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21231 USA
关键词
Glioblastoma multiforme; Immunotherapy; Oncogenic signaling pathway; Immunoresistance; ENDOTHELIAL GROWTH-FACTOR; CENTRAL-NERVOUS-SYSTEM; PRIMARY INTRACRANIAL TUMORS; FAS LIGAND EXPRESSION; REGULATORY T-CELLS; HUMAN GLIOBLASTOMA CELLS; CONFER IMMUNE PRIVILEGE; PERIPHERAL-BLOOD; IN-VIVO; INDOLEAMINE 2,3-DIOXYGENASE;
D O I
10.1016/j.nec.2009.08.008
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Even though the central nervous system (CNS) was conventionally defined as "immunologically privileged", new discoveries have demonstrated the role of the immune system in neurologic disease and illness, including gliomas. Brain tumor immunotherapy is an exciting and revived area of research, in which neurosurgeons have taken a major position. Despite the ability to induce a tumor-specific systemic immune response, the challenge to effectively eradicate intracranial gliomas remains mainly because of tumor-induced immunoresistance. This article gives an overview of the immunologic responses that occur in the CNS and their potential role in brain tumors. The main cellular and molecular mechanisms that mediate tumor escape from natural immune surveillance are also covered in this article. Glioma cells have been shown to diminish the expression of danger signals necessary for immune activation and to increase the concentration of immunosuppressive factors in the tumor microenvironment, which results in T-cell anergy or apoptosis. Finally, the authors discuss most of the over-expressed oncogenic signaling pathways that cause tumor tolerance.
引用
收藏
页码:17 / +
页数:14
相关论文
共 163 条
[81]  
Le Mercier M, 2008, J NEUROPATH EXP NEUR, V67, P456, DOI 10.1097/NEN.0b013e318170f892
[82]   Evidence of galectin-1 involvement in glioma chemoresistance [J].
Le Mercier, Marie ;
Lefranc, Florence ;
Mijatovic, Tatjana ;
Debeir, Olivier ;
Haibe-Kains, Benjamin ;
Bontempi, Gianluca ;
Decaestecker, Christine ;
Kiss, Robert ;
Mathieu, Veronique .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 2008, 229 (02) :172-183
[83]   Galectin-1: A link between tumor hypoxia and tumor immune privilege [J].
Le, QT ;
Shi, GY ;
Cao, HB ;
Nelson, DW ;
Wang, YY ;
Chen, EY ;
Zhao, SC ;
Kong, C ;
Richardson, D ;
O'Byrne, KJ ;
Giaccia, AJ ;
Koong, AC .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (35) :8932-8941
[84]   Dexamethasone mediated inhibition of local IL-2 immunotherapy is dose dependent in experimental brain tumors [J].
Lesniak, MS ;
Gabikian, P ;
Tyler, BM ;
Pardoll, DM ;
Brem, H .
JOURNAL OF NEURO-ONCOLOGY, 2004, 70 (01) :23-28
[85]   Regulation of immune responses by TGF-β [J].
Letterio, JJ ;
Roberts, AB .
ANNUAL REVIEW OF IMMUNOLOGY, 1998, 16 :137-161
[86]  
LEVISTRAUSS M, 1987, J IMMUNOL, V139, P2361
[87]   Galectins: A new family of regulators of inflammation [J].
Liu, FT .
CLINICAL IMMUNOLOGY, 2000, 97 (02) :79-88
[88]   Tumor evasion of the immune system by converting CD4+ CD25- T cells into CD4+ CD25+ T regulatory cells:: Role of tumor-derived TGF-β [J].
Liu, Victoria C. ;
Wong, Larry Y. ;
Jang, Thomas ;
Shah, Ali H. ;
Park, Irwin ;
Yang, Ximing ;
Zhang, Qiang ;
Lonning, Scott ;
Teicher, Beverly A. ;
Lee, Chung .
JOURNAL OF IMMUNOLOGY, 2007, 178 (05) :2883-2892
[89]   Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma [J].
Liyanage, UK ;
Moore, TT ;
Joo, HG ;
Tanaka, Y ;
Herrmann, V ;
Doherty, G ;
Drebin, JA ;
Strasberg, SM ;
Eberlein, TJ ;
Goedegebuure, PS ;
Linehan, DC .
JOURNAL OF IMMUNOLOGY, 2002, 169 (05) :2756-2761
[90]   A TIGER BEHIND MANY DOORS - MULTIPLE GENETIC PATHWAYS TO MALIGNANT GLIOMA [J].
LOUIS, DN ;
GUSELLA, JF .
TRENDS IN GENETICS, 1995, 11 (10) :412-415